Castle Biosciences annual debt-to-equity ratio
2019
2020
2021
2022
2023
2024
2025
Castle Biosciences Debt-to-Equity Ratio Growth & History (CSTL)
Castle Biosciences's debt-to-equity ratio was 0.08 for fiscal 2025.
View full Castle Biosciences company overviewCastle Biosciences annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.08 | 0.02 | +35.50% |
| 2024 | 2024-12-31 | 0.06 | 0.02 | +47.34% |
| 2023 | 2023-12-31 | 0.04 | 0.01 | +16.00% |
| 2022 | 2022-12-31 | 0.03 | 0.01 | +68.22% |
| 2021 | 2021-12-31 | 0.02 | 0.02 | — |
| 2020 | 2020-12-31 | 0.00 | −0.30 | — |
| 2019 | 2019-12-31 | 0.30 | — | — |
Castle Biosciences quarterly debt-to-equity ratio
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.08 | −0.00 | −4.94% |
| Q1 2026 | 2026-03-31 | 0.08 | 0.02 | +35.60% |
| Q4 2025 | 2025-12-31 | 0.08 | 0.02 | +35.50% |
| Q3 2025 | 2025-09-30 | 0.08 | 0.02 | +31.16% |
| Q2 2025 | 2025-06-30 | 0.08 | 0.02 | +38.02% |
| Q1 2025 | 2025-03-31 | 0.06 | −0.00 | −5.71% |
| Q4 2024 | 2024-12-31 | 0.06 | 0.02 | +47.34% |
| Q3 2024 | 2024-09-30 | 0.06 | 0.02 | +61.01% |
| Q2 2024 | 2024-06-30 | 0.06 | 0.02 | +56.39% |
| Q1 2024 | 2024-03-31 | 0.06 | 0.03 | +86.11% |
| Q4 2023 | 2023-12-31 | 0.04 | 0.01 | +16.00% |
| Q3 2023 | 2023-09-30 | 0.04 | 0.00 | +15.31% |
| Q2 2023 | 2023-06-30 | 0.04 | 0.02 | +108.33% |
| Q1 2023 | 2023-03-31 | 0.03 | 0.01 | +68.01% |
| Q4 2022 | 2022-12-31 | 0.03 | 0.01 | +68.22% |
| Q3 2022 | 2022-09-30 | 0.03 | 0.03 | — |
| Q2 2022 | 2022-06-30 | 0.02 | 0.02 | — |
| Q1 2022 | 2022-03-31 | 0.02 | 0.02 | — |
| Q4 2021 | 2021-12-31 | 0.02 | 0.02 | — |
| Q3 2021 | 2021-09-30 | 0.00 | −0.13 | — |
| Q2 2021 | 2021-06-30 | 0.00 | −0.16 | — |
| Q1 2021 | 2021-03-31 | 0.00 | −0.29 | — |
| Q4 2020 | 2020-12-31 | 0.00 | −0.30 | — |
| Q3 2020 | 2020-09-30 | 0.13 | −0.17 | −55.43% |
| Q2 2020 | 2020-06-30 | 0.16 | — | — |
| Q1 2020 | 2020-03-31 | 0.29 | — | — |
| Q4 2019 | 2019-12-31 | 0.30 | — | — |
| Q3 2019 | 2019-09-30 | 0.30 | — | — |
Castle Biosciences debt-to-equity ratio trends
Over the last five fiscal years, Castle Biosciences's debt-to-equity ratio increased from 0.00 to 0.08, a change of 0.08. The latest reported quarter, Q2 2026, shows 0.08.
About the metric
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
Calculation and source
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Castle Biosciences source filings ↗